Zoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.
Follow ZTS
Zoetis Inc. (ZTS) EV/Sales
As of 16 October 2026, Zoetis Inc. (ZTS) trades at a EV/Sales of 4.4×. Over the past ten years it has ranged from 3.9× (October 2026) to 15.9× (December 2021); the current reading is higher than 3% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.7× | (20.70%) |
| FY2024 | 8.5× | (23.78%) |
| FY2023 | 11.1× | 23.00% |
| FY2022 | 9.1× | (40.77%) |
| FY2021 | 15.3× | 24.03% |
| FY2020 | 12.3× | 13.84% |
| FY2019 | 10.8× | 36.92% |
| FY2018 | 7.9× | 6.81% |
| FY2017 | 7.4× | 19.42% |
| FY2016 | 6.2× | 6.83% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.1× | (33.58%) |
| Mar 2026 | 6.1× | (9.06%) |
| Dec 2025 | 6.7× | (11.15%) |
| Sep 2025 | 7.6× | (4.71%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VTRS Viatris Inc. compare | 2.3× |
| RDY Dr. Reddy's Laboratories Ltd compare | 2.9× |
| TAK Takeda Pharmaceutical Co. compare | 3.0× |
| ELAN Elanco Animal Health Incorporated compare | 3.0× |
| HLN Haleon PLC Sponsored ADR compare | 3.1× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 3.5× |
| NBIX Neurocrine Biosciences, Inc. compare | 4.1× |
| ZTS Zoetis Inc. | 4.4× |
| UTHR United Therapeutics Corporation compare | 6.5× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on ZTS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement